Klaus Podar

Consultant/ Head Division Molecular Oncology and Hematology

Karl Landsteiner University of Health Sciences

Austria

Research Interests

Explore related searches

Professors in Austria Professors in Immunology Immunology professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Klaus Podar is a Consultant and Head of the Division of Molecular Oncology and Hematology at Karl Landsteiner University of Health Sciences in Austria. His research focuses on the development of transcription factor inhibitors and novel treatments for multiple myeloma and acute myeloid leukemia. Recent publications include studies on anti-tumor immunity, combination therapies, and the impact of various therapies on quality of life in cancer patients.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Collaborators (8)

Christoph Wiesner

Professor

IMC University of Applied Sciences Krems

AUSTRIA

View details

Joachim Widder

Medical University of Vienna

AUSTRIA

View details

Sonia Vallet

Karl Landsteiner University of Health Sciences

AUSTRIA

View details

Emilio Casanova

Professor

Medical University of Vienna

AUSTRIA

View details

Ulrich Jaeger

Medical University of Vienna

AUSTRIA

View details

Dea Slade

Universität Wien

AUSTRIA

View details

Sophie Edtmayer

Karl Landsteiner University of Health Sciences

AUSTRIA

View details

Sascha Klee

Karl Landsteiner University of Health Sciences

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Klaus Podar

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia

Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy.

PARP7 as a new target for activating anti-tumor immunity in cancer.

Favorable impact of PD1/PD-L1 antagonists on bone remodeling

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma.

Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study

Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.

Collaborators (8)

Christoph Wiesner

Joachim Widder

Sonia Vallet

Emilio Casanova

Ulrich Jaeger

Dea Slade

Sophie Edtmayer

Sascha Klee

Make your next move.